Literature DB >> 20163839

Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.

Takeshi Yuasa1, Shinya Maita, Norihiko Tsuchiya, Zhiyong Ma, Shintaro Narita, Yohei Horikawa, Shinya Yamamoto, Junji Yonese, Iwao Fukui, Shunji Takahashi, Kiyohiko Hatake, Tomonori Habuchi.   

Abstract

OBJECTIVES: To examine Japanese patients who had received androgen-deprivation therapy (ADT) for longer periods, as it is known that ADT of patients with prostate cancer reduces their bone mineral density (BMD). However, our previous cross-sectional study revealed that short-term ADT (average, 23.5 months) does not significantly increase the prevalence of osteoporosis in Japanese patients.
METHODS: The subjects consisted of 201 native Japanese patients with prostate cancer. They comprised 113 ADT-treated and 88 hormone-naive patients. Lumbar spine, total hip, and femoral neck BMDs were measured by dual-energy x-ray absorptiometry and expressed in standard deviation units relative to the scores of young adult men (T-score) or age-matched men (Z-score). Serum levels of bone metabolism markers were also measured.
RESULTS: The ADT-treated patients had significantly lower BMD values, T-scores, and even Z-scores than the hormone-naive patients (P <.001). For patients who were hormone-naive, ADT-treated for less than 2 years, and ADT-treated for more than 2 years, the osteoporosis prevalence was 4.5% (4/88), 12.1% (4/33), and 10.8% (4/37), respectively. The ADT-treated patients had significantly higher serum amino-terminal telopeptide levels than the hormone-naive patients (P = .014), but significantly lower serum carboxy-terminal telopeptide of type-I collagen levels than the ADT-treated patients with bone metastasis (P <.001).
CONCLUSIONS: Our cross-sectional study confirmed that both ADT-treated and hormone-naive Japanese patients with prostate cancer have low rates of osteoporosis. These findings are different from those of studies in western countries. Genetic and hormonal or other environmental factors may result in population differences in the characteristics of prostate cancer and BMD. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20163839     DOI: 10.1016/j.urology.2009.10.075

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

Authors:  C-T Wu; Y-H Yang; P-C Chen; M-F Chen; W-C Chen
Journal:  Osteoporos Int       Date:  2015-05-20       Impact factor: 4.507

2.  Denosumab: a new option in the treatment of bone metastases from urological cancers.

Authors:  Takeshi Yuasa; Shinya Yamamoto; Shinji Urakami; Iwao Fukui; Junji Yonese
Journal:  Onco Targets Ther       Date:  2012-09-21       Impact factor: 4.147

3.  Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer.

Authors:  Belinda F Morrison; Ingrid E Burrowes; William D Aiken; Richard G Mayhew; Horace M Fletcher; Marvin E Reid
Journal:  Infect Agent Cancer       Date:  2011-09-23       Impact factor: 2.965

4.  Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study.

Authors:  Sung Han Kim; Jae Young Joung; Sohee Kim; Koon Ho Rha; Hyeong Gon Kim; Cheol Kwak; Ji Youl Lee; Seong Soo Jeon; Sung Kyu Hong; Hyeon Jeong; Moon Ki Jo; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Choung-Soo Kim
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

Review 5.  Prostate cancer in East Asia: evolving trend over the last decade.

Authors:  Yao Zhu; Hong-Kai Wang; Yuan-Yuan Qu; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

6.  Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?

Authors:  Kazuhiro Nagao; Hideyasu Matsuyama; Hiroaki Matsumoto; Takahito Nasu; Mitsutaka Yamamoto; Yoriaki Kamiryo; Yoshikazu Baba; Akinobu Suga; Yasuhide Tei; Satoru Yoshihiro; Akihiko Aoki; Tomoyuki Shimabukuro; Keiji Joko; Shigeru Sakano; Kimio Takai; Shiro Yamaguchi; Jumpei Akao; Seiji Kitahara
Journal:  Int J Clin Oncol       Date:  2018-03-27       Impact factor: 3.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.